HUP9901359A3 - Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them - Google Patents

Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them

Info

Publication number
HUP9901359A3
HUP9901359A3 HU9901359A HUP9901359A HUP9901359A3 HU P9901359 A3 HUP9901359 A3 HU P9901359A3 HU 9901359 A HU9901359 A HU 9901359A HU P9901359 A HUP9901359 A HU P9901359A HU P9901359 A3 HUP9901359 A3 HU P9901359A3
Authority
HU
Hungary
Prior art keywords
atherosclerosis
producing
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU9901359A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of HUP9901359A2 publication Critical patent/HUP9901359A2/hu
Publication of HUP9901359A3 publication Critical patent/HUP9901359A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9901359A 1996-04-26 1997-04-15 Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them HUP9901359A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds

Publications (2)

Publication Number Publication Date
HUP9901359A2 HUP9901359A2 (hu) 1999-08-30
HUP9901359A3 true HUP9901359A3 (en) 2000-03-28

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901359A HUP9901359A3 (en) 1996-04-26 1997-04-15 Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them

Country Status (17)

Country Link
EP (1) EP0915843A1 (cs)
JP (1) JP2000509049A (cs)
AR (1) AR006833A1 (cs)
AU (1) AU2698697A (cs)
BR (1) BR9709196A (cs)
CA (1) CA2252696A1 (cs)
CZ (1) CZ341098A3 (cs)
HU (1) HUP9901359A3 (cs)
ID (1) ID16660A (cs)
IL (1) IL126696A0 (cs)
MA (1) MA26426A1 (cs)
NO (1) NO984939L (cs)
NZ (1) NZ332476A (cs)
PE (1) PE64398A1 (cs)
PL (1) PL329530A1 (cs)
TR (1) TR199802160T2 (cs)
WO (1) WO1997041098A1 (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60121550T2 (de) 2000-02-16 2007-06-21 Smithkline Beecham Plc, Brentford Pyrimidin-4-onderivat als LDL-PLA2 Inhibitor
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
ME00145B (me) 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
UA75644C2 (en) 2001-03-28 2006-05-15 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
DE60216275T2 (de) * 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517573C (en) 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
EA200971050A1 (ru) 2007-05-11 2010-06-30 Томас Джефферсон Юниверсити Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
EA023796B1 (ru) 2010-12-06 2016-07-29 Глэксо Груп Лимитед ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
JP2013545792A (ja) 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
EP2725024A4 (en) 2011-06-27 2014-12-03 Shanghai Inst Materia Medica HETEROCYCLIC AZOL COMPOUND, METHOD OF MANUFACTURING THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
KR20140059204A (ko) 2011-07-27 2014-05-15 글락소 그룹 리미티드 비시클릭 피리미돈 화합물
WO2013013503A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
WO2014114249A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
CN105008368B (zh) 2013-01-25 2017-02-01 葛兰素史密斯克莱知识产权发展有限公司 基于2,3‑二氢咪唑并[1,2‑c]嘧啶‑5(1H)‑酮的脂蛋白相关磷脂酶A2(Lp‑PLA2)抑制剂
WO2014114248A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CA3156783A1 (en) 2019-11-09 2021-05-14 Yun Jin Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993002048A1 (en) * 1991-07-23 1993-02-04 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994013636A1 (en) * 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP0974663A1 (en) * 1993-06-25 2000-01-26 Smithkline Beecham Plc Lipoprotein associated phospholipase A2, inhibitors thereof and use of same in diagnosis and therapy
DE69434609T2 (de) * 1993-10-06 2006-09-21 Icos Corp., Bothell Acethylhydrolase des Plättchen aktivierenden Faktors
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
HUT77089A (hu) * 1994-12-22 1998-03-02 Smithkline Beecham Plc. Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
BR9609445A (pt) * 1995-07-01 1999-04-06 Smithkline Beecham Plc Derivados de azetidinona no tratamento de aterosclerose
WO1997021676A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis

Also Published As

Publication number Publication date
TR199802160T2 (xx) 1999-04-21
EP0915843A1 (en) 1999-05-19
AU2698697A (en) 1997-11-19
IL126696A0 (en) 1999-08-17
MA26426A1 (fr) 2004-12-20
PE64398A1 (es) 1999-01-06
JP2000509049A (ja) 2000-07-18
NO984939L (no) 1998-12-23
PL329530A1 (en) 1999-03-29
CZ341098A3 (cs) 1999-03-17
NO984939D0 (no) 1998-10-23
AR006833A1 (es) 1999-09-29
ID16660A (id) 1997-10-30
BR9709196A (pt) 1999-05-25
WO1997041098A1 (en) 1997-11-06
HUP9901359A2 (hu) 1999-08-30
CA2252696A1 (en) 1997-11-06
NZ332476A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
HUP9901359A3 (en) Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
HUP9700344A3 (en) Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP9902850A3 (en) Quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP9901535A3 (en) Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9802565A3 (en) N-benzyl-dioxothiazolidinylmethyl-benzamide derivatives, pharmaceutical compositions containing them and process for producing the same
HUP9602511A3 (en) Aryl-diazinone derivatives, pharmaceutical compositions containing them, and process for producing all these
HUP9802839A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them and process for producing them
HUP9802300A3 (en) N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUT76286A (en) Quinoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP0000323A3 (en) N-substituted 2-cyanopyrrolidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9701264A3 (en) Aminoacid derivatives, process for producing them and pharmaceutical compositions containing them
HUP9701265A3 (en) Imidazoline derivatives, process for producing them and pharmaceutical compositions containing them
ZA959100B (en) Azetidinone derivatives for the treatment of atherosclerosis
HUP9603433A2 (en) 4-6-diaryl-pyrimidine-derivatives, process for producing them and pharmaceutical compositions containing them
HUP9901153A3 (en) Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
HUP9600071A3 (en) Indolo-piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9901739A3 (en) Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them
HUP9600876A3 (en) Benzonitril- and -fluoride derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9602681A1 (en) Hydroxy-pyridinone derivatives, process for producing them and pharmaceutical compositions containing them
HU9800781D0 (en) Propanolamine derivatives, process for producing them, pharmaceutical compositions containing them and their use
HU9501925D0 (en) Ortho-amine-substituted benzoyl-guanidine derivatives, process for producing them their pharmaceutical or diagnostical use, and pharmaceutical compositions containing them
HUP9602763A3 (en) 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same
HU9602640D0 (en) Substituted benzoyl-guanidine derivatives, process for producing them and pharmaceutical compositions containing them
HUT74615A (en) 2,3-cyclic-condensed-1,4-dihydro-pyridine derivatives, process for producing them and pharmaceutical compositions containing the same
HUP9900105A3 (en) Momopiperazine derivatives, process for producing them and pharmaceutical compositions containing them